

## REVIEW

# Platelet-rich plasma versus corticosteroid injections in the management of patients with rotator cuff disease: A systematic review and meta-analysis

Maamoun Adra<sup>1,2</sup> | Nour El Ghazal<sup>1,2</sup> | Hayato Nakanishi<sup>1,2</sup> | Karen Smayra<sup>1,2</sup> | Sam S. Hong<sup>1,2</sup> | Shahid Miangul<sup>1,2</sup> | Reem H. Matar<sup>1,2,3</sup> | Christian A. Than<sup>1,2,4</sup>  | Duncan Tennent<sup>5</sup>

<sup>1</sup>St George's University of London, London, UK

<sup>2</sup>University of Nicosia Medical School, University of Nicosia, Nicosia, Cyprus

<sup>3</sup>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, New York, USA

<sup>4</sup>School of Biomedical Sciences, The University of Queensland, Brisbane, Queensland, Australia

<sup>5</sup>Orthopedic Department, St George's Hospital, London, UK

## Correspondence

Duncan Tennent, Orthopedic Department, St George's Hospital, Blackshaw Rd, London SW17 0QT, UK.

Email: [Duncan@tennent.net](mailto:Duncan@tennent.net)

## Abstract

Platelet-rich plasma (PRP) is an alternative to corticosteroid (CS) injections in managing rotator cuff disease. This meta-analysis investigated differences between PRP and CS for function and pain scores in significance and minimal clinical important difference (MCID). A literature search of Ovid Cochrane Library, Medline, Embase, Epub, and Scopus was conducted from inception to October 28, 2021. Eligible studies reported patients older than 18 years with a diagnosis of rotator cuff disease. This review was registered in PROSPERO (ID: CRD42021278740). Twelve studies met eligibility criteria ( $n = 639$ ) of patients receiving either PRP or CS. At short-term follow-up, a difference favored CS compared to PRP in baseline change for disability of arm, shoulder, and hand (DASH) score (MD =  $-5.08$ , 95% CI:  $-8.00$ ,  $-2.15$ ;  $p = 0.0007$ ;  $I^2 = 0\%$ ) and simple shoulder test (SST) (MD =  $1.25$ , 95% CI:  $0.33$ ,  $2.18$ ;  $p = 0.008$ ;  $I^2 = 0\%$ ). At intermediate follow-up, a difference favored PRP to CS baseline change of the DASH score (MD =  $3.41$ , 95% CI:  $0.67$ ,  $6.15$ ;  $p = 0.01$ ;  $I^2 = 0\%$ ). At medium-term, a difference favored PRP to CS baseline change of the American Shoulder and Elbow Surgeons Shoulder (ASES) score (MD =  $-4.42$ , 95% CI:  $-8.16$ ,  $-0.67$ ;  $p = 0.02$ ;  $I^2 = 0\%$ ). Both treatments achieved individual MCID for each score. Despite favoring CS at short-term follow-up and PRP at intermediate- and medium-term follow-up, functional and pain scores did not demonstrate any clinical difference between the two treatment modalities in management of rotator cuff disease at all follow-up periods.

## KEYWORDS

corticosteroid, injection, meta-analysis, platelet-rich, rotator cuff

## 1 | INTRODUCTION

Rotator cuff disease (RCD) is one of the most common shoulder pathologies in the general population, with prevalence of over 60% for those over 80.<sup>1</sup> RCD is an umbrella term that includes numerous pathologies namely partial or full thickness tears, cuff tear arthropathy, tendinopathy, subacromial impingement syndrome, and subacromial bursitis.<sup>2</sup> While the more obvious outcome of RCD is shoulder pain, it can also lead to a significant decrease in the ability to perform daily activities. Conservative management is considered the gold standard<sup>3</sup> and consists of activity modification, oral medication, physical therapy, and subacromial injections of corticosteroids (CS).<sup>4,5</sup> However, CS provides little benefit beyond symptomatic relief which may not last and may even lead to permanent damage to tendon ultrastructure.<sup>6</sup> As a consequence, alternative treatment methods are being considered.<sup>7</sup> One of these is platelet-rich plasma (PRP). PRP injections promote the release of growth factors such as transforming growth factor beta (TGF- $\beta$ ) and vascular endothelial growth factor (VEGF)<sup>8</sup> and it is thought that PRP injections accelerate the process of healing via increasing fibroblast migration and proliferation and tissue vascularization.<sup>9</sup> PRP injections are considered to be more expensive than corticosteroid injections as a single PRP has a mean cost of \$707USD.<sup>10</sup> Scarpone et al.<sup>11</sup> noted significant improvement in pain, function, and MRI outcomes following PRP injections for participants with refractory rotator cuff tears, which are unresponsive to standard care including rest, physical therapy, analgesia, CS injections, and surgery. Because of its direct contribution to wound healing, in addition to its role in pain relief, the use of PRP injections in clinical practice has been gaining traction. The relative efficacy of CS injections compared to PRP is currently under debate.

A recent systematic review comparing CS with PRP injections noted no significant difference in the efficacy of these two techniques in the medium to long term with regard to pain relief, functional recovery, and range of motion.<sup>7</sup> In the short-term, two studies favored CS in improving functional outcomes, while pain relief scores favored PRP injections<sup>12</sup>; but the remainder showed no significant difference between the two treatment modalities.

In addition, what has not been discussed is the actual clinical effect of the intervention on the patient. Ultimately the question is—does the treatment reach the threshold for the minimal clinically important differences (MCID)?

To the best of our knowledge, no meta-analysis has analyzed the functional scores with respect to this threshold. The aim of this study is to compare the efficacy of CS and PRP in the treatment of RCD based on functional scores and pain scores to determine if either reach the MCID threshold of patient benefit which will help determine whether there is a clinical difference.

## 2 | METHODS

### 2.1 | Data sources and search strategies

A comprehensive search of numerous databases from inception to October 28, 2021 was conducted in compliance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines.<sup>13</sup> The databases included Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced librarian with input from the study's principal investigator. Controlled vocabulary supplemented with keywords was used to search for studies describing corticosteroid versus PRP injection for the treatment of rotator cuff diseases, which include conditions such as rotator cuff tendinopathy, partial- and full-thickness tear, subacromial impingement syndrome, subacromial bursitis, and cuff tear arthropathy. The actual strategy listing all search terms used and how they are combined is available in Supporting Information: Item 1. This review was registered in PROSPERO (ID: CRD42021278740).

### 2.2 | Eligibility criteria and quality assessment

Eligible studies were randomized control and clinical trials that met all the following inclusion criteria: (1) adults above 18 years old who underwent either a PRP or CS injection for the treatment of rotator cuff disease, (2) patients were either diagnosed with imaging or clinical evaluation, (3) rotator cuff disease includes partial tendon tear, full-thickness tear, rotator cuff tendinosis (tendinopathy), subacromial pain syndrome and rotator cuff impingement. Case reports, case series, conference abstracts and/or abstracts, and articles that were not reported in English were excluded from the study. The quality of each study was independently evaluated by two authors (Maamoun Adra and Nour El Ghazal) using the Newcastle-Ottawa Scale.<sup>14</sup> Results of the quality assessment of all included studies are shown in Supporting Information: Table S1.

### 2.3 | Statistical analysis

The pooled estimate of mean difference was analyzed using an inverse-variance-weighted average of the individual studies.<sup>15</sup> A direct comparison between the two groups was conducted by assessing studies that reported outcomes of both treatments (two-arm analysis). The data were analyzed using intention-to-treat analysis. When change in standard deviation could not be obtained, it was imputed by performing correlation analysis using standard deviation of baseline and final value. If the correlation coefficient was less than 0.5, the final value of standard deviation was incorporated in our analysis.<sup>15</sup> The heterogeneity of effect size estimates across

the studies was quantified using the  $Q$  statistic and  $I^2$  ( $p < 0.05$  was considered significant). A value of  $I^2$  of 0%–25% indicates insignificant statistical heterogeneity, 26%–50% low heterogeneity, 51%–100% high heterogeneity.<sup>16</sup> The Random-effects model was used when the value of  $I^2$  was  $>50\%$  and the fixed-effects model was used for  $I^2 < 50\%$ . Data analysis was performed using RevMan software version 5.4 (Review Manager [RevMan] [Computer program]. The Cochrane Collaboration, 2020).

## 2.4 | Data extraction and MCID interpretation

### 2.4.1 | Functional scores

The functional scores were assessed using the constant-Murley score (CMS), the American Shoulder and Elbow Surgeons Shoulder Score (ASES), University of California at Los Angeles Shoulder Score (UCLA), disability of the arm, shoulder, and hand (DASH) score and simple shoulder test (SST). Each score was analyzed as a change from baseline at short-term (3–6 weeks), intermediate-term (8–12 weeks), and medium-term (more than 12 weeks) follow-up. The range of reported MCID for rotator cuff tears assessment are 8–10 for CMS,<sup>17</sup> 9–26.9 for ASES,<sup>17</sup> 3.0 for UCLA,<sup>18</sup> 8.1–13.0 for DASH,<sup>17</sup> and 2 for SST.<sup>17</sup> The specific characteristics of MCID, which includes the condition and treatment for which it was determined, can be found in detail in Table 1.

### 2.4.2 | Pain

The perception of pain was evaluated with visual analog scale (VAS) questionnaire score, and it was analyzed as a change from baseline at short-term (3–6 weeks), intermediate-term (8–12 weeks), and medium-term (more than 12 weeks) follow-up. MCID for rotator cuff tears assessment is reported as 1.4 cm for VAS score.<sup>19</sup>

## 3 | RESULTS

### 3.1 | Study selection and characteristics

The initial search yielded 648 potentially relevant articles from which 12 unique studies, involving 321 patients in the CS group and 318 patients in the PRP group, met the eligibility criteria. The PRISMA flow chart (Figure 1) illustrates the details of the study selection process. Furthermore, the baseline characteristics of each included study are comprehensively described in Table 2.

### 3.2 | Risk of bias

Results of the quality assessment of all included studies are shown in Supporting Information: Table 1. All the studies were judged to be of good quality. The patients appeared to represent the whole

experience of the investigator, and the exposure and outcome were adequately ascertained, and the lengths of follow-up were adequate to manifest a change in the clinical outcomes.

The results with respect to the research questions are summarized in Table 3.

### 3.3 | VAS score

Pain was self-reported by patients using VAS score in a number of papers (Figure 2). The baseline VAS scores along with their change from base-line can be found in Table 4. At short- and intermediate-term follow-up, the change from baseline was comparable between the CS and PRP groups and no difference was observed (short-term: MD =  $-0.30$ , 95% CI:  $-1.40$ ,  $0.08$ ;  $p = 0.59$ ;  $I^2 = 89\%$ <sup>12,26,28,34,32</sup>) (Intermediate-term: MD =  $0.28$ , 95% CI:  $-0.71$ ,  $1.28$ ;  $p = 0.58$ ;  $I^2 = 84\%$ <sup>26–28,31,32</sup>). At medium-term follow-up, no difference in the change of VAS score from base-line was observed between the PRP and CS groups (MD =  $0.39$ , 95% CI:  $-1.84$ ,  $2.62$ ;  $p = 0.73$ ;  $I^2 = 97\%$ <sup>12,28,34,32</sup>).

Both the CS and PRP cohorts reached MCID separately. Therefore, no clinical difference was observed between the two treatments.

### 3.4 | Functional scores

All baseline values of the functional scores along with their subsequent changes at follow-up for the CS and PRP groups are summarized in Table 4. Furthermore, the mean differences (MD) between the two treatments for each outcome is summarized in Table 5.

#### 3.4.1 | ASES score

ASES score was reported in five studies<sup>28,33,32</sup> (Figure 3). At the short-term follow-up, no difference in the change of ASES from base-line was observed between the two groups (MD =  $6.10$ , 95% CI:  $-3.66$ ,  $15.85$ ;  $p = 0.22$ ;  $I^2 = 87\%$ ). Similarly, at the intermediate-term point, no difference in the change from base-line was observed between the two groups (MD =  $-7.52$ , 95% CI:  $-19.88$ ,  $4.83$ ;  $p = 0.23$ ;  $I^2 = 92\%$ ). At the medium-term follow-up, there is a difference between the CS and PRP group such that in the latter group, there was a greater change from baseline compared to the former group with a difference of 18.15 and 10.80, respectively (MD =  $-4.42$ , 95% CI:  $-8.16$ ,  $-0.67$ ;  $p = 0.02$ ;  $I^2 = 0\%$ ).

Both CS and PRP cohorts reached MCID separately. Therefore, there exists no clinical difference between the two treatment modalities.

#### 3.4.2 | CMS score

CMS score was reported in five studies<sup>12,25,28,33,35</sup> (Figure 4). At the short-term follow-up, no difference in the change from base-line was observed between the two groups (MD =  $3.18$ , 95% CI:  $-5.78$ ,  $12.14$ ;  $p = 0.49$ ;  $I^2 = 91\%$ ). Similarly, at the intermediate

**TABLE 1** Characteristics of MCID for pain and functional scores

| Score | MCID   | Study                             | Condition(s)                                                            | Treatment                                                                                                                                                                          |
|-------|--------|-----------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| VAS   | 1.4    | Tashjian et al. <sup>19</sup>     | Rotator cuff tendonitis, rotator cuff tear (partial- or full-thickness) | Nonoperative treatment (various combinations of rest, ice, activity modifications, physical therapy, anti-inflammatory pain medications, and subacromial corticosteroid injection) |
| CMS   | 8–10   | Kukkonen et al. <sup>20</sup>     | Partial- or full-thickness rotator cuff tears                           | Arthroscopic rotator cuff surgery                                                                                                                                                  |
|       |        | Torrens et al. <sup>21</sup>      | Massive irreparable rotator cuff tears                                  | Reverse shoulder arthroplasty                                                                                                                                                      |
| ASES  | 9–26.9 | Gagnier et al. <sup>22</sup>      | Full-thickness rotator cuff tears                                       | Surgically and nonsurgically                                                                                                                                                       |
|       |        | Tashjian et al. <sup>19</sup>     | Tendinitis, partial- or full-thickness rotator cuff tear                | Nonsurgical (various combination of rest, ice, activity modifications, physical therapy, anti-inflammatory pain medications, and subacromial corticosteroid injection)             |
|       |        | Werner et al. <sup>23</sup>       | Glenohumeral arthritis, rotator cuff tear arthropathy                   | Total or reverse shoulder arthroplasty                                                                                                                                             |
| UCLA  | 3      | Xu et al. <sup>18</sup>           | Partial- or full-thickness supraspinatus tear                           | Arthroscopic rotator cuff repair with subacromial decompression surgery                                                                                                            |
| SST   | 2      | Tashjian et al. <sup>19</sup>     | Tendinitis, partial- or full-thickness rotator cuff tear                | Nonsurgical (various combination of rest, ice, activity modifications, physical therapy, anti-inflammatory pain medications, and subacromial corticosteroid injection)             |
| DASH  | 8.1–13 | Van de Water et al. <sup>24</sup> | Proximal humeral fractures                                              | Rehabilitation                                                                                                                                                                     |

Abbreviations: ASES, American Shoulder and Elbow Surgeons Shoulder Score; CMS, constant-murley score; DASH, disabilities of the arm, shoulder, and hand; MCID, minimally clinically important difference; SST, simple shoulder test; UCLA, University of California at Los Angeles Shoulder Score; VAS, visual analog scale.


**FIGURE 1** Preferred reporting items for systematic reviews and meta-analyses flow diagram

TABLE 2 Baseline characteristics of included studies

| Study                          | Country | Sample size (n) |    |     | Mean age ± SD (years) |              |             | Side affected |      | Duration of symptoms ± SD (months) |                 | Follow-up (weeks)            | Outcome assessment method/score                                                                                          |
|--------------------------------|---------|-----------------|----|-----|-----------------------|--------------|-------------|---------------|------|------------------------------------|-----------------|------------------------------|--------------------------------------------------------------------------------------------------------------------------|
|                                |         | Total           | CS | PRP | Males: Females (n)    | CS           | PRP         | Right         | Left | CS                                 | PRP             |                              |                                                                                                                          |
| Barreto et al. <sup>25</sup>   | Brazil  | 51              | 25 | 26  | 18:33                 | 53 ± 11      | 53.2 ± 9.4  | 23            | 16   | NR                                 | NR              | Baseline, 4, 12, 24 weeks    | CMS DASH UCLA                                                                                                            |
| Dadgostar et al. <sup>26</sup> | Iran    | 58              | 28 | 30  | 11:47                 | 53.6 ± 7.24  | 57.33 ± 9.8 | NR            | NR   | NR                                 | NR              | Baseline, 1, 4, 12 weeks     | VAS WORC DASH Supraspinatus thickness ROM Flexion Extension Abduction Adduction External rotation Internal rotation      |
| Ibrahim et al. <sup>27</sup>   | Egypt   | 30              | 15 | 15  | 13:17                 | 41.5 ± 12.5  | 46.8 ± 10.6 | 23            | 7    | 1                                  | 2               | Baseline, 8 weeks            | VAS SDQ Clinical rotator cuff tests US findings ROM Flexion Extension Abduction External rotation Internal rotation      |
| Jo et al. <sup>28</sup>        | Korea   | 60              | 30 | 30  | 20:40                 | 52.5 ± 11.2  | 55.3 ± 10.3 | NR            | NR   | 13.1 ± 15.6                        | 11.6 ± 11.4     | Baseline, 1, 4, 12, 24 weeks | VAS (mean, rest, night, activity, worst) CMS ASES DASHSTUCLA RC strength ROM Flexion External rotation Internal rotation |
| Kwong et al. <sup>29</sup>     | Canada  | 99              | 52 | 47  | 35:64                 | 49.08 ± 9.54 | 49.94 ± 9.7 | NR            | NR   | 297.84 ± 318.24                    | 404.28 ± 925.32 | Baseline, 6, 12, 48 weeks    | VAS ASES WORC                                                                                                            |
| Pasin et al. <sup>30</sup>     | Turkey  | 60              | 30 | 30  | NR                    | 47.73 ± 9.55 | 49.4 ± 9.1  | NR            | NR   | 0.92 ± 1.12                        | 0.77 ± 0.66     | Baseline, 3, 8 weeks         | VAS (rest and activity) DASH UCLA                                                                                        |

(Continues)

TABLE 2 (Continued)


| Study                           | Country     | Sample size (n) |    |     | Males:  |               | Mean age ± SD (years) |     |    | Indications                           | Side affected |      |             | Duration of symptoms ± SD (months) |                           |                                                                                                              | Follow-up (weeks) | Outcome assessment method/score |
|---------------------------------|-------------|-----------------|----|-----|---------|---------------|-----------------------|-----|----|---------------------------------------|---------------|------|-------------|------------------------------------|---------------------------|--------------------------------------------------------------------------------------------------------------|-------------------|---------------------------------|
|                                 |             | Total           | CS | PRP | Females | PRP           | CS                    | PRP | CS |                                       | Right         | Left | CS          | PRP                                |                           |                                                                                                              |                   |                                 |
| Sabaah and Nassif <sup>31</sup> | Egypt       | 40              | 20 | 20  | 12:28   | 41.85 ± 10.21 | 41.85 ± 10.21         | NR  | NR | Rotator cuff tendinopathy             | 24            | 16   | NR          | NR                                 | Baseline, 12 weeks        | VAS<br>WORC                                                                                                  |                   |                                 |
| Sari and Eroglu <sup>32</sup>   | Turkey      | 60              | 30 | 30  | 43:77*  | NR            | NR                    | NR  | NR | Rotator cuff lesions                  | 88            | 32   | 4.87 ± 1.76 | NR                                 | Baseline, 3, 12, 24 weeks | VAS<br>ASES<br>WORC                                                                                          |                   |                                 |
| Say et al. <sup>12</sup>        | Turkey      | 60              | 30 | 30  | 22:38   | 50.2 ± 2.7    | 49.2 ± 7              | NR  | NR | Subacromial impingement syndrome      | 35            | 25   | NR          | NR                                 | Baseline, 6, 24 weeks     | CMS<br>VAS<br>Radiographic outcomes<br>ROM<br>Flexion<br>Abduction<br>External rotation<br>Internal rotation |                   |                                 |
| Shams et al. <sup>33</sup>      | Egypt       | 40              | 20 | 20  | 21:19   | 50 ± 10       | 52 ± 12               | NR  | NR | Symptomatic partial rotator cuff tear | 23            | 17   | NR          | NR                                 | Baseline, 6, 12, 24 weeks | CMS<br>VAS<br>ASES<br>SST<br>Radiographic outcomes<br>(Pre-op + 6 months post-op)<br>MRI grades              |                   |                                 |
| Thepsoparn et al. <sup>34</sup> | Thailand    | 31              | 16 | 15  | 6:25    | 62.4 ± 10.5   | 51.3 ± 10.3           | NR  | NR | Partial supraspinatus tears           | NR            | NR   | 13.5 ± 12.5 | 8.3 ± 11.6                         | Baseline, 4, 24 weeks     | VAS<br>OSS<br>ROM                                                                                            |                   |                                 |
| von Wehren et al. <sup>35</sup> | Switzerland | 50              | 25 | 25  | 26:24   | 55 ± 10       | 53 ± 14               | NR  | NR | Partial rotator cuff tears            | 30            | 20   | NR          | NR                                 | Baseline, 6, 12, 24 weeks | CMS<br>VAS<br>ASES<br>SST                                                                                    |                   |                                 |

Abbreviations: ASES, American Shoulder and Elbow Surgeons Shoulder Score; CMS, constant-murley score; CS, corticosteroid; DASH, disabilities of the arm, shoulder, and hand; n, number of patients; NR, not reported; OSS, Oxford shoulder score; PRP, platelet rich plasma; ROM, range of motion; SD, standard deviation; SDQ, shoulder disability questionnaire; SF-36, short form 36; SST, simple shoulder test; UCLA, University of California at Los Angeles Shoulder Score; VAS, visual analog scale; WORC, Western Ontario rotator cuff index.

**TABLE 3** Summary of the findings

| Test |                        | 3–6 weeks      |     | 8–12 weeks     |     | >12 weeks      |     |
|------|------------------------|----------------|-----|----------------|-----|----------------|-----|
|      |                        | PRP            | CS  | PRP            | CS  | PRP            | CS  |
| VAS  | Reaches MCID           | Yes            | Yes | Yes            | Yes | Yes            | Yes |
|      | Significant difference | No             |     | No             |     | No             |     |
| CMS  | Reaches MCID           | Yes            | Yes | Yes            | Yes | Yes            | Yes |
|      | Significant difference | No             |     | No             |     | No             |     |
| ASES | Reaches MCID           | Yes            | Yes | Yes            | Yes | Yes            | Yes |
|      | Significant difference | No             |     | No             |     | Yes (PRP > CS) |     |
| DASH | Reaches MCID           | Yes            | Yes | Yes            | Yes | Yes            | Yes |
|      | Significant difference | Yes (CS > PRP) |     | Yes (PRP > CS) |     | No             |     |
| SST  | Reaches MCID           | No             | Yes | Yes            | Yes | Yes            | yes |
|      | Significant difference | Yes (CS > PRP) |     | No             |     | No             |     |
| UCLA | Reaches MCID           | Yes            | Yes | Yes            | Yes | Yes            | Yes |
|      | Significant difference | No             |     | No             |     | No             |     |

Abbreviations: ASES, American Shoulder and Elbow Surgeons Shoulder Score; CMS, constant-murley score; CS, corticosteroid; DASH, disabilities of the arm, shoulder, and hand; MCID, minimally clinically important difference; PRP, platelet rich plasma; SST, simple shoulder test; UCLA, University of California at Los Angeles Shoulder Score; VAS, visual analog scale.

**FIGURE 2** Pooled estimate of visual analog scale (VAS) score for corticosteroids versus platelet-rich plasma group at (A) short-term (3–6 weeks), (B) intermediate-term (8–12 weeks), (C) medium-term (>12 weeks). VAS is a negative outcome.

point, no difference in the change from base-line was observed between the treatments (MD = -7.73, 95% CI: -18.68, 3.23;  $p = 0.17$ ;  $I^2 = 87\%$ ).<sup>25,28,33,35</sup> The two groups were comparable at the medium-term point (MD = -2.65, 95% CI: -11.70, 6.40;  $p = 0.57$ ;  $I^2 = 91\%$ ).<sup>12,25,28,33,35</sup>

Both CS and PRP cohorts reached MCID separately. Therefore, there exists no clinical difference between the two treatments.

### 3.4.3 | DASH score

DASH score was reported in four studies<sup>25,26,28,30</sup> (Figure 5). At the short-term follow-up, there exists a difference between the

two cohorts such that the change from baseline was higher in the CS group in comparison to the PRP group with a mean change of -16.71 and -10.92, respectively (MD = -5.08, 95% CI: -8.00, -2.15;  $p = 0.0007$ ;  $I^2 = 0\%$ ).<sup>25,26,28,30</sup> At the intermediate-term follow-up, there exists a difference with a greater change in the PRP group in comparison to the CS group with a mean DASH score of -25.56 and -24.31, respectively (MD = 3.41, 95% CI: 0.67, 6.15;  $p = 0.01$ ;  $I^2 = 0\%$ ).<sup>25,26,28,30</sup> During medium-term follow-up, the mean change from baseline was comparable between the two groups with no difference (MD = 0.95, 95% CI: -4.88, 6.79;  $p = 0.75$ ;  $I^2 = 80\%$ ).<sup>28,28</sup>

Both CS and PRP cohorts reached MCID separately. Therefore, there exists no clinical difference between the two treatment modalities.

TABLE 4 Baseline and follow-up outcomes

| Outcome         | Baseline          |                   | 3–6 weeks          |                    | 8–12 weeks    |                    | >12 weeks          |      |
|-----------------|-------------------|-------------------|--------------------|--------------------|---------------|--------------------|--------------------|------|
|                 | Mean ± SD (N)     |                   | Mean ± SD (N)      |                    | Mean ± SD (N) |                    | Mean ± SD (N)      |      |
|                 | CS                | PRP               | CS                 | PRP                | CS            | PRP                | CS                 | PRP  |
| Shoulder scores |                   |                   |                    |                    |               |                    |                    |      |
| ASES            | 55.28 ± 15.75 (5) | 53.83 ± 14.02 (5) | 17.31 ± 16.49 (5)  | 11.65 ± 17.83 (5)  | 0.22          | 18.15 ± 20.04 (5)  | 16.45 ± 20.14 (5)  | 0.02 |
| VAS             | 5.53 ± 2.43 (8)   | 5.94 ± 2.13 (8)   | –2.39 ± 2.41 (6)   | –1.83 ± 2.12 (6)   | 0.59          | –2.14 ± 2.54 (6)   | –2.26 ± 2.72 (5)   | 0.73 |
| CMS             | 57.51 ± 19.03 (5) | 56.19 ± 17.35 (5) | 12.15 ± 11.81 (5)  | 8.39 ± 13.63 (5)   | 0.49          | 15.80 ± 15.81 (4)  | 14.68 ± 14.99 (5)  | 0.57 |
| UCLA            | 17.51 ± 5.69 (3)  | 15.95 ± 4.67 (3)  | 11.01 ± 7.99 (3)   | 10.40 ± 7.60 (3)   | 0.52          | 14.78 ± 9.49 (3)   | 8.77 ± 9.59 (2)    | 0.32 |
| DASH            | 52.23 ± 23.65 (4) | 52.94 ± 22.76 (4) | –16.71 ± 16.70 (4) | –10.92 ± 15.19 (4) | 0.0007        | –25.56 ± 24.43 (4) | –18.64 ± 22.62 (2) | 0.75 |
| SST             | 6.31 ± 2.53 (3)   | 6.85 ± 2.41 (3)   | 2.66 ± 3.16 (3)    | 1.34 ± 2.71 (3)    | 0.008*        | 2.55 ± 2.83 (3)    | 2.61 ± 3.25 (3)    | 0.26 |

Note: \*Indicates statistical significance.  
Abbreviations: ASES, American Shoulder and Elbow Surgeons Shoulder Score; CMS, constant–Murley score; CS, corticosteroid; DASH, disabilities of the arm, shoulder, and hand; N, number of studies included; PRP, platelet-rich plasma; SD, standard deviation; SST, simple shoulder test; UCLA, University of California at Los Angeles Shoulder Score; VAS, visual analog scale.

### 3.4.4 | UCLA score

UCLA score was reported in three studies<sup>25,28,30</sup> (Figure 6). The change from baseline was comparable between the CS and PRP groups at short- and medium-term follow-up (Short-term: MD = 0.47, 95% CI: –0.94, 1.88;  $p = 0.52$ ;  $I^2 = 0\%$ <sup>25,28,30</sup>) (medium-term: MD = –1.27, 95% CI: –3.75, 1.21;  $p = 0.32$ ;  $I^2 = 0\%$ <sup>25,28</sup>). Similarly, in the intermediate-term, no difference in the change from base-line was observed amongst the two treatment groups (MD = –2.31, 95% CI: –6.27, 1.66;  $p = 0.25$ ;  $I^2 = 76\%$ <sup>25,28,30</sup>).

Both CS and PRP cohorts reached MCID separately. Therefore, there exists no clinical difference between the two treatments.

### 3.4.5 | SST score

SST score was reported in three studies<sup>28,33,35</sup> (Figure 7). At the short-term follow-up, there exists a difference between the two cohorts such that the change from baseline was higher in the CS group in comparison to the PRP group with a mean change of 2.66 and 1.34, respectively (MD = 1.25, 95% CI: 0.33, 2.18;  $p = 0.008$ ;  $I^2 = 0\%$ ). Conversely, at intermediate- and medium-term, the change from baseline was comparable between the PRP and CS groups with no difference (intermediate-term: MD = –0.63, 95% CI: –1.99, 0.73;  $p = 0.08$ ;  $I^2 = 61\%$ ) (medium-term: MD = –0.48, 95% CI: –1.31, 0.35;  $p = 0.26$ ;  $I^2 = 0\%$ ).

Both CS and PRP cohorts reached MCID separately, except during the short-term where PRP had a change of 1.34. Therefore, there exists no clinical difference between the two treatment modalities.

## 4 | DISCUSSION

The primary aim of this review was to investigate the functional outcomes (UCLA, SST, DASH, ASES, and CMS) and perception of pain (VAS) among patients injected with PRP compared to those injected with CS for managing rotator cuff disease with the critical questions being

- (1) Did either treatment reach the MCID threshold for patient benefit?
- (2) Was there a significant clinical difference between the treatment modalities?

This meta-analysis demonstrated that:



- (1) Both treatment methods separately reached MCID at nearly all time points (apart from PRP failing to reach MCID in the short-term in the SST outcome).
- (2) Despite there being a statistically significant difference in the short-term in favor of CS injection and a statistically significant difference in favor of PRP injection in the intermediate and

**TABLE 5** Mean difference of functional and pain scores between corticosteroid and platelet-rich plasma treatment

| Outcome         | 3–6 weeks (MD)       | 3–6 weeks (p-Value) | 8–12 weeks (MD)       | 8–12 weeks (p-Value) | >12 weeks (MD)        | >12 weeks (p-Value) |
|-----------------|----------------------|---------------------|-----------------------|----------------------|-----------------------|---------------------|
| Shoulder scores |                      |                     |                       |                      |                       |                     |
| VAS             | –0.30 (Favouring CS) | 0.59                | 0.28 (Favouring PRP)  | 0.58                 | 0.39 (Favouring PRP)  | 0.73                |
| CMS             | 3.18 (Favouring CS)  | 0.49                | –7.73 (Favouring PRP) | 0.17                 | –2.65 (Favouring PRP) | 0.57                |
| ASES            | 6.10 (Favouring CS)  | 0.22                | –7.52 (Favouring PRP) | 0.23                 | –4.42 (Favouring PRP) | 0.02*               |
| DASH            | –5.08 (Favouring CS) | 0.0007*             | 3.41 (Favouring PRP)  | 0.01*                | 0.95 (Favouring PRP)  | 0.75                |
| SST             | 1.25 (Favouring CS)  | 0.008*              | –0.63 (Favouring PRP) | 0.37                 | –0.48 (Favouring PRP) | 0.26                |
| UCLA            | 0.47 (Favouring CS)  | 0.52                | –2.31 (Favouring PRP) | 0.25                 | –1.27 (Favouring PRP) | 0.32                |

Note: \*Indicates statistical significance.


Abbreviations: ASES, American Shoulder and Elbow Surgeons Shoulder Score; CMS, constant-Murley score; CS, corticosteroid; DASH, disabilities of the arm, shoulder, and hand; N, number of studies included; PRP, platelet rich plasma; SD, standard deviation; SST, simple shoulder test; UCLA, University of California at Los Angeles Shoulder Score; VAS, visual analog scale.

**FIGURE 3** Pooled estimate of American shoulder and elbow surgeons shoulder (ASES) score for corticosteroids versus platelet-rich plasma group at (A), short-term (3–6 weeks), (B) intermediate-term (8–12 weeks), (C) medium-term (>12 weeks)**FIGURE 4** Pooled estimate of constant-murley score (CMS) for corticosteroids versus platelet-rich plasma group at (A), short-term (3–6 weeks), (B), intermediate-term (8–12 weeks), (C), medium-term (>12 weeks)


medium term, there is no clinical difference between them since both reached MCID. Thus, neither can be considered clinically superior.

There is consensus that CS suppress acute inflammation by inhibiting protein synthesis of pro-inflammatory products.<sup>36,37</sup> CS injection as a source of symptomatic relief and transient


functional improvement is commonly used among many different conditions including rotator cuff lesions.<sup>38</sup> According to the American Academy of Orthopedic Surgeons (AAOS), a single CS injection with a local anesthetic provides short-term pain relief as well as improved shoulder joint function.<sup>39</sup> A systematic review<sup>40</sup> reported that CS injections for the management of shoulder impingement yielded less pain at 6 weeks follow-up but not at



**FIGURE 5** Pooled estimate of disabilities of the arm, shoulder, and hand (DASH) score for corticosteroids versus platelet-rich plasma group at (A) short-term (3–6 weeks), (B) intermediate-term (8–12 weeks), (C), medium-term (>12 weeks). DASH is a negative outcome.



**FIGURE 6** Pooled estimate of University of California at Los Angeles Shoulder (UCLA) score for corticosteroids versus platelet-rich plasma group at (A), short-term (3–6 weeks), (B), intermediate-term (8–12 weeks), (C), medium-term (>12 weeks)



**FIGURE 7** Pooled estimate of simple shoulder test (SST) score for corticosteroids versus platelet-rich plasma group at (A), short-term (3–6 weeks), (B), intermediate-term (8–12 weeks), (C), medium-term (>12 weeks)

longer follow-up times such as 3 and 6 months. An RCT<sup>41</sup> found that at 1-month postinjection of CS, lower VAS pain score, improved functional score (ASES), and higher ROM were observed in comparison to the control group, which received a normal saline injection.

A previous meta-analysis<sup>7</sup> demonstrated that CS yielded short-term pain relief as well as better functionality in comparison to PRP, which is in line with our findings, but the results were only reported as being statistically significant.

However, several recent RCTs comparing CS and PRP injections for the treatment of rotator cuff diseases showed controversial results.<sup>25,30</sup> Our findings suggest statistically but not clinically

significant difference in the short term in favor of CS injections possibly allowing better functionality and pain relief in the short-term in the management of patients with rotator cuff disease. Similarly, a review done by Abate et al.<sup>42</sup> has found that CS injection for the treatment of shoulder pain, mainly due to rotator cuff tendinopathy, provided short-term pain relief and functional improvement. However, no long-term benefit was reported by the studies, but no harm was observed either. CS administration generally can cause local skin manifestations such as rash or hypopigmentation which are considered to be minor adverse effects.<sup>43</sup> There exist reviews that mention serious side effects upon local CS injection such as subcutaneous tendon ruptures.<sup>42,44</sup> However, such an event is mainly

TABLE 6 Treatment characteristics across the studies

| Studies                         | Type of PRP    | # of injections             | US-guided | Location of injection                         | Preparation                                                                                                                                                                                                                                                                            |
|---------------------------------|----------------|-----------------------------|-----------|-----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Barreto et al. <sup>25</sup>    | Autologous     | NS                          | No        | Posterior subacromial space                   | Double centrifugation and manual platelet separation with micropipettes, including the buffy coat. Then transferred to test tube for concentration.                                                                                                                                    |
| Dadgostar et al. <sup>26</sup>  | NS             | 2                           | Yes       | Intraarticular joint at the tendon            | Prepared and processed in ROOYA GEN (Arya Mabna Tashkhis Co., Tehran, Iran)                                                                                                                                                                                                            |
| Ibrahim et al. <sup>27</sup>    | Autologous     | 1                           | Yes       | Lateral subacromial                           | Double centrifugation protocol. The remaining PRP and platelet plug were reconstituted using gentle manual agitation resulting in 2 ml of PRP ready for injection, thrombin was added to activate PRP in ratio 10:1, it was directly mixed before injection.                           |
| Jo et al. <sup>28</sup>         | Allogenic pure | 1                           | Yes       | Subacromial space                             | Allogenic PRPs were obtained with use of an automated plateletpheresis system with a leukoreduction set (COBE Spectra LRS Turbo; Caridian BCT) from healthy donors without rotator cuff disease (n = 3). After activation with calcium gluconate, PRPs were mixed and frozen until use |
| Kwong et al. <sup>29</sup>      | Leukocyte-poor | 1                           | Yes       | Affected tendon + subacromial space           | A leukocyte-poor preparation was used from a pre-packaged kit (RegenLab, Lausanne, Switzerland). The samples were centrifuged at 1500 g for 5 min to yield approximately 5.5 ml of 80% platelets at 1.6 concentration                                                                  |
| Pasin et al. <sup>30</sup>      | Autologous     | 1                           | NS        | Subacromial space                             | Neotec Biotechnology PRP kit (Neotec Biotechnology Ltd., Istanbul, Turkey) and Elektromag device model 415 P (Elektro-Mag AS) were used. Double centrifugation was done.                                                                                                               |
| Sabaah and Nassif. (2020)       | Autologous     | 2 (2 weeks apart)           | Yes       | Subacromial subdeltoid bursa                  | Double centrifugation protocol. The remaining PRP and platelet plug resulted in 5 ml PRP with a concentration of 6.7 times of whole blood ready for use.                                                                                                                               |
| Sari and Eroglu. (2020)         | Autologous     | 1                           | Yes       | Lateral subacromial                           | PRP was prepared using the literature-based double spin method. Before injection, the PRP was activated by adding 1 ml 10% calcium chloride                                                                                                                                            |
| Say et al. <sup>12</sup>        | Autologous     | 1                           | NS        | Posterolateral below the dorsal acromial edge | The PRP was prepared manually using single spin rotation. The 2.5 ml PRP was activated by 5.5% calcium chloride.                                                                                                                                                                       |
| Shams et al. <sup>33</sup>      | NS             | 1                           | NS        | Posterolateral                                | Patients received PRP injection using MyCells Autologous Platelet Preparation System (ProTech). A single-spin was done.                                                                                                                                                                |
| Thepsoparn et al. <sup>34</sup> | Leukocyte-poor | 1                           | Yes       | Posterolateral at tendon site                 | PRP was prepared using the ACP Double Syringe System (Arthrex).                                                                                                                                                                                                                        |
| von Wehren et al. <sup>30</sup> | Autologous     | 3 (within a 7-day interval) | NS        | Lateral subacromial space                     | Ten milliliters of autologous blood was taken from the antecubital vein with the outer syringe, placed into the Arthrex Centrifuge (Rotofix) and centrifuged for 5 min at 1500 rpm.                                                                                                    |

Abbreviations: NS, not specified; PRP, platelet-rich plasma.

attributed to multiple injections with poor technique, mostly not US-guided.<sup>45</sup>

PRP is an emerging alternative treatment for many different conditions. During the inflammatory stage of the tendon healing process, platelets will migrate toward the injured area and release growth factors such as transforming growth factor  $\beta$  (TGF $\beta$ ), platelet-derived growth factor (PDGF), and insulin growth factor (IGF). This collectively promotes acute inflammation.<sup>46</sup> In addition to the anti-inflammatory properties mediated by hepatocyte growth factor (HGF)<sup>47</sup> the regenerative capacity of PRP is facilitated by growth factors, such as PDGF, known to enhance cell migration, tenocyte proliferation, differentiation, and extracellular matrix (ECM) synthesis.<sup>48</sup> PRP also accelerates the healing process via its contribution to the differentiation and proliferation of tendon stem cells into tenocytes, thus maintaining tendon homeostasis, in addition to producing tendon healing-related glycoproteins and proteoglycans involved in matrix assembly and collagen adhesion.<sup>49</sup> Since the effects of PRP have been mainly studied in in-vivo animal studies and in vitro studies,<sup>49</sup> the clinical significance of the tendon healing and tissue regeneration capacity of PRP in humans is still yet to be explored. In our study, PRP suggests that the overall improvement in functional and pain scores seen in this meta-analysis are mainly due to the symptom-modifying effects of PRP which are likely to be associated with the anti-inflammatory component rather than the tissue regeneration component.

A number of recent reviews have suggested that PRP therapy yields a more favorable functional outcome as well as reduced pain in the long-term compared to CS treatment; for a variety of conditions including lateral epicondylitis,<sup>50,51</sup> knee osteoarthritis,<sup>52</sup> lumbar spondylosis and sacroiliac arthropathy.<sup>53</sup> In addition, a randomized control trial<sup>54</sup> reported that there seems to be clinically important improvements disability (>15-point DASH change) at long-term follow-up for treating degenerative tendinopathies.

## 4.1 | Limitations

This meta-analysis contains several limitations.

A confounding factor in the interpretation of the literature is the method of PRP preparation. It has been demonstrated that an apheresis and buffy coat-derived preparation achieved a higher platelet concentration owing to a possible extra centrifugation step, which in turn allows for higher growth factor levels, as opposed to a tube method preparation, which, on the other hand, showed the highest level of white blood cell contamination.<sup>55</sup> A handful of these studies utilized a similar protocol which involved a double centrifugation that gives rise to PRP derived from the upper plasma layer and the buffy coat (buffy-coat derived).<sup>25,30,31</sup> However,<sup>12</sup> prepared PRP manually using a single spin rotation.

In addition, the baseline characteristics of the participants were different in terms of lifestyle, occupation, weight, and

severity of the rotator cuff disease. The treatment protocols were different not only with respect to the injection itself but also the posttreatment regime. Given that physiotherapy has a strong influence on the recovery from rotator cuff disorders there may be significant effects. Moreover, the final standard deviation (SD) was used for the meta-analysis instead of the change in SD in some studies due to the lack of individual patient data. The authors of the included studies were contacted three times with no response. There is also inconsistency in follow-up period between the studies. With regard to MCID, the values used for the pain and function scores were determined based on treatments involving surgical and nonsurgical regimens for which PRP were not routinely included. This limitation encourages future studies to include PRP injections as a treatment to determine MCID in rotator cuff disease.

As discussed, different platelets preparations may have had variability, but there was also variability in the steroid preparations. Different doses were administered over one or several injections at different sites, the composition of the injections slightly varied and some of them were guided by imaging (ultrasound or MRI) while others were not. Table 6 summarizes the similarities and differences in the treatment protocols across all included studies. Despite the above limitations, this meta-analysis supports no clinical difference between PRP and CS. Future research should address these limitations while continuing to evaluate the efficacy of PRP in the treatment of rotator cuff disease in comparison to CS.

## 5 | CONCLUSION

Both CS and PRP injections separately reach MCID proving to be clinically beneficial for patients. Therefore, no clinical difference could be concluded. Furthermore, both treatments achieve some statistical differences in various functional scores such that the CS group seems to be in favor of better functionality in the short-term while the PRP group appears to yield better functionality in the intermediate and medium term. In future, studies with prolonged follow-up periods, larger sample sizes, a homogenous treatment protocol, and MCID evaluating rotator cuff disease are required to further assess the clinical difference of CS versus PRP injection in the management of rotator cuff disease.

## DATA AVAILABILITY STATEMENT

With the publication, the data set used for this meta-analysis will be shared upon request from the study authors.

## AUTHOR CONTRIBUTIONS

Maamoun Adra, Nour El Ghazal, Christian A. Than, and Duncan Tennent conceived and designed the study, reviewed the literature,

collected, analyzed, and interpreted the data, and drafted the manuscript. Maamoun Adra, Nour El Ghazal, Hayato Nakanishi, Christian A. Than, Duncan Tennent conceived and designed the study, and critically revised the manuscript. Maamoun Adra, Nour El Ghazal, Hayato Nakanishi, Karen Smayra, Sam S. Hong, Shahid Miangul, Reem H. Matar, Christian A. Than, Duncan Tennent reviewed the literature, collected, analyzed, and interpreted the data, and drafted the manuscript. All authors read and approved the final manuscript.

## ACKNOWLEDGMENT

We would like to thank Larry J. Prokop MS, MAR for the literature search.

## CONFLICT OF INTEREST

The authors declare no conflict of interest.

## ORCID

Christian A. Than  <http://orcid.org/0000-0003-4283-7629>

## REFERENCES

1. Sambandam SN, Khanna V, Gul A, Mounasamy V. Rotator cuff tears: an evidence based approach. *World J Orthop.* 2015;6:902-918.
2. Jo CH, Shin WH, Park JW, Shin JS, Kim JE. Degree of tendon degeneration and stage of rotator cuff disease. *Knee Surg Sports Traumatol Arthrosc.* 2017;25:2100-2108.
3. Weiss LJ, Wang D, Hendel M, Buzzerio P, Rodeo SA. Management of rotator cuff injuries in the elite athlete. *Curr Rev Musculoskelet Med.* 2018;11:102-112.
4. Dang A, Davies M. Rotator cuff disease: treatment options and considerations. *Sports Med Arthrosc Rev.* 2018;26:129-133.
5. Neri BR, Chan KW, Kwon YW. Management of massive and irreparable rotator cuff tears. *J Shoulder Elbow Surg.* 2009;18:808-818.
6. Puzitiello RN, Patel BH, Nwachukwu BU, Allen AA, Forsythe B, Salzler MJ. Adverse impact of corticosteroid injection on rotator cuff tendon health and repair: a systematic review. *Arthroscopy.* 2020;36:1468-1475.
7. Wang C, Zhang Z, Ma Y, Liu X, Zhu Q. Platelet-rich plasma injection vs corticosteroid injection for conservative treatment of rotator cuff lesions: a protocol for systematic review and meta-analysis. *Medicine (Baltimore).* 2021;100:e24680.
8. Jain A, Bedi RK, Mittal K. Platelet-rich plasma therapy: a novel application in regenerative medicine. *Asian J Transfus Sci.* 2015;9:113-114.
9. van der Bijl I, Vlig M, Middelkoop E, de Korte D. Allogeneic platelet-rich plasma (PRP) is superior to platelets or plasma alone in stimulating fibroblast proliferation and migration, angiogenesis, and chemotaxis as relevant processes for wound healing. *Transfusion.* 2019;59:3492-3500.
10. Momaya AM, McGee AS, Dombrowsky AR, et al. The cost variability of orthobiologics. *Sports Health.* 2020;12:94-98.
11. Scarpone M, Rabago D, Snell E, et al. Effectiveness of platelet-rich plasma injection for rotator cuff tendinopathy: a prospective open-label study. *Glob Adv Health Med.* 2013;2:26-31.
12. Say F, Gürlü D, Bülbül M. Platelet-rich plasma versus steroid injection for subacromial impingement syndrome. *J Orthop Surg.* 2016;24:62-66.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* 2009;6:e1000097.
14. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25:603-605.
15. Higgins JPT. *Cochrane Handbook for Systematic Reviews of Interventions.* Wiley-Blackwell; 2020.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003;327:557-560.
17. Dabija DI, Jain NB. Minimal clinically important difference of shoulder outcome measures and diagnoses: a systematic review. *Am J Phys Med Rehabil.* 2019;98:671-676.
18. Xu S, Chen JY, Lie HME, Hao Y, Lie D. Minimal clinically important difference of Oxford, constant, and UCLA shoulder score for arthroscopic rotator cuff repair. *J Orthop.* 2020;19:21-27.
19. Tashjian RZ, Deloach J, Porucznik CA, Powell AP. Minimal clinically important differences (MCID) and patient acceptable symptomatic state (PASS) for visual analog scales (VAS) measuring pain in patients treated for rotator cuff disease. *J Shoulder Elbow Surg.* 2009;18:927-932.
20. Kukkonen J, Kauko T, Vahlberg T, et al. Investigating minimal clinically important difference for Constant score in patients undergoing rotator cuff surgery. *J Shoulder Elbow Surg.* 2013;22:1650-1655.
21. Torrens C, Guirro P, Santana F. The minimal clinically important difference for function and strength in patients undergoing reverse shoulder arthroplasty. *J Shoulder Elbow Surg.* 2016;25:262-268.
22. Gagnier JJ, Robbins C, Bedi A, et al. Establishing minimally important differences for the American Shoulder and Elbow Surgeons score and the Western Ontario Rotator Cuff Index in patients with full-thickness rotator cuff tears. *J Shoulder Elbow Surg.* 2018;27:e160-e166.
23. Werner BC, Chang B, Nguyen JT, et al. What Change in American Shoulder and Elbow Surgeons Score Represents a Clinically Important Change After Shoulder Arthroplasty? *Clin Orthop Relat Res.* 2016;474:2672-2681.
24. van de Water AT, Shields N, Davidson M, et al. Reliability and validity of shoulder function outcome measures in people with a proximal humeral fracture. *Disabil Rehabil.* 2014;36:1072-1079.
25. Barreto RB, Azevedo AR, Gois MC, Freire M, Silva DS, Cardoso JC. Platelet-rich plasma and corticosteroid in the treatment of rotator cuff impingement syndrome: randomized clinical trial. *Rev Bras Ortop (Sao Paulo).* 2019;54:636-643.
26. Dadgostar H, Fahimipour F, Pahlevan Sabagh A, Arasteh P, Razi M. Corticosteroids or platelet-rich plasma injections for rotator cuff tendinopathy: a randomized clinical trial study. *J Orthop Surg Res.* 2021;16:333.
27. Ibrahim DH, El-Gazzar NM, El-Saadany HM, El-Khouly RM. Ultrasound-guided injection of platelet rich plasma versus corticosteroid for treatment of rotator cuff tendinopathy: effect on shoulder pain, disability, range of motion and ultrasonographic findings. *Egypt Rheumatol.* 2019;41:157-161.
28. Jo CH, Lee SY, Yoon KS, Oh S, Shin S. Allogeneic platelet-rich plasma versus corticosteroid injection for the treatment of rotator cuff disease: a randomized controlled trial. *JBJS.* 2020;102:102-2137.
29. Kwong CA, Woodmass JM, Gusnowski EM, et al. Platelet-rich plasma in patients with partial-thickness rotator cuff tears or tendinopathy leads to significantly improved short-term pain relief and function compared with corticosteroid injection: a double-blind randomized controlled trial. *Arthroscopy.* 2021;37:510-517.
30. Pasin T, Ataoglu S, Pasin Ö, Ankarali H. Comparison of the effectiveness of platelet-rich plasma, corticosteroid, and physical therapy in subacromial impingement syndrome. *Arch Rheumatol.* 2019;34:308-316.
31. Sabaah HMAE, Nassif MA. What is better for rotator cuff tendinopathy: dextrose prolotherapy, platelet-rich plasma, or

- corticosteroid injections? A randomized controlled study. *Egypt Rheumatol Rehabil.* 2020;47:40.
32. Sari A, Eroglu A. Comparison of ultrasound-guided platelet-rich plasma, prolotherapy, and corticosteroid injections in rotator cuff lesions. *J Back Musculoskelet Rehabil.* 2020;33:387-396.
33. Shams A, El-Sayed M, Gamal O, Ewes W. Subacromial injection of autologous platelet-rich plasma versus corticosteroid for the treatment of symptomatic partial rotator cuff tears. *Eur J Orthop Surg Traumatol.* 2016;26:837-842.
34. Thepsoparn M, Thanphraisan P, Tanpowpong T, Itthipanichpong T. Comparison of a platelet-rich plasma injection and a conventional steroid injection for pain relief and functional improvement of partial supraspinatus tears. *Orthop J Sports Med.* 2021;9:23259671211024937.
35. von Wehren L, Blanke F, Todorov A, Heisterbach P, Sailer J, Majewski M. The effect of subacromial injections of autologous conditioned plasma versus cortisone for the treatment of symptomatic partial rotator cuff tears. *Knee Surg Sports Traumatol Arthrosc.* 2016;24:3787-3792.
36. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Mol Cell Endocrinol.* 2011;335:2-13.
37. Cruz-Topete D, Cidowski JA. One hormone, two actions: anti- and pro-inflammatory effects of glucocorticoids. *Neuroimmunomodulation.* 2015;22:20-32.
38. Rees JD, Wilson AM, Wolman RL. Current concepts in the management of tendon disorders. *Rheumatology (Oxford).* 2006;45: 508-521.
39. Weber S, Chahal J. Management of rotator cuff injuries. *J Am Acad Orthop Surg.* 2020;28:e193-e201.
40. Steuri R, Sattelmayer M, Elsig S, et al. Effectiveness of conservative interventions including exercise, manual therapy and medical management in adults with shoulder impingement: a systematic review and meta-analysis of RCTs. *Br J Sports Med.* 2017;51: 1340-1347.
41. Kim YS, Jin HK, Lee HJ, Cho HL, Lee WS, Jang HJ. Is it safe to inject corticosteroids into the glenohumeral joint after arthroscopic rotator cuff repair? *Am J Sports Med.* 2019;47:1694-1700.
42. Abate M, Salini V, Schiavone C, Andia I. Clinical benefits and drawbacks of local corticosteroids injections in tendinopathies. *Expert Opin Drug Saf.* 2017;16:341-349.
43. Brinks A, Koes BW, Volkers AC, Verhaar JA, Bierma-Zeinstra SM. Adverse effects of extra-articular corticosteroid injections: a systematic review. *BMC Musculoskelet Disord.* 2010;11:206.
44. Dean BJ, Lostis E, Oakley T, Rombach I, Morrey ME, Carr AJ. The risks and benefits of glucocorticoid treatment for tendinopathy: a systematic review of the effects of local glucocorticoid on tendon. *Semin Arthritis Rheum.* 2014;43:570-576.
45. Bhatia M, Singh B, Nicolaou N, Ravikumar KJ. Correlation between rotator cuff tears and repeated subacromial steroid injections: a case-controlled study. *Ann R Coll Surg Engl.* 2009;91:414-416.
46. Molloy T, Wang Y, Murrell G. The roles of growth factors in tendon and ligament healing. *Sports Med.* 2003;33:381-394.
47. Bendinelli P, Matteucci E, Dogliotti G, et al. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-kappaB inhibition via HGF. *J Cell Physiol.* 2010;225:757-766.
48. Qian Y, Han Q, Chen W, et al. Platelet-rich plasma derived growth factors contribute to stem cell differentiation in musculoskeletal regeneration. *Front Chem.* 2017;5:5.
49. Zhou Y, Wang JH. PRP treatment efficacy for tendinopathy: a review of basic science studies. *BioMed Res Int.* 2016;2016:9103792.
50. Kemp JA, Olson MA, Tao MA, Burcal CJ. Platelet-rich plasma versus corticosteroid injection for the treatment of lateral epicondylitis: a systematic review of systematic reviews. *Int J Sports Phys Ther.* 2021;16:597-605.
51. Xu Q, Chen J, Cheng L. Comparison of platelet rich plasma and corticosteroids in the management of lateral epicondylitis: a meta-analysis of randomized controlled trials. *Int J Surg.* 2019;67:37-46.
52. McLarnon M, Heron N. Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis. *BMC Musculoskelet Disord.* 2021;22:550.
53. Ling JF, Wininger AE, Hirase T. Platelet-rich plasma versus corticosteroid injection for lumbar spondylosis and sacroiliac arthropathy: a systematic review of comparative studies. *Cureus.* 2021;13:e14062.
54. Wesner M, Defreitas T, Bredy H, et al. A pilot study evaluating the effectiveness of platelet-rich plasma therapy for treating degenerative tendinopathies: a randomized control trial with synchronous observational cohort. *PLoS One.* 2016;11:e0147842.
55. Zimmermann R, Jakubietz R, Jakubietz M, et al. Different preparation methods to obtain platelet components as a source of growth factors for local application. *Transfusion.* 2001;41:1217-1224.
56. Kukkonen J, Kauko T, Vahlberg T, et al. Investigating minimal clinically important difference for Constant score in patients undergoing rotator cuff surgery. *J Shoulder Elbow Surg.* 2013; 22:1650-55.
57. Torrents C, Guirro P, Santana F. The minimal clinically important difference for function and strength in patients undergoing reverse shoulder arthroplasty. *J Shoulder Elbow Surg.* 2016; 25:262-268.
58. Gagnier JJ, Robbins C, Bedi A, et al. Establishing minimally important differences for the American Shoulder and Elbow Surgeons score and the Western Ontario Rotator Cuff Index in patients with full-thickness rotator cuff tears. *J Shoulder Elbow Surg.* 2018; 27: e160-e166.
59. Werner BC, Chang B, Nguyen JT, et al. What Change in American Shoulder and Elbow Surgeons Score Represents a Clinically Important Change After Shoulder Arthroplasty? *Clin Orthop Relat Res.* 2016; 474:2672-2681.
60. van de Water AT, Shields N, Davidson M, et al. Reliability and validity of shoulder function outcome measures in people with a proximal humeral fracture. *Disabil Rehabil.* 2014; 36:1072-1079.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Adra M, El Ghazal N, Nakanishi H, et al. Platelet-rich plasma versus corticosteroid injections in the management of patients with rotator cuff disease: a systematic review and meta-analysis. *J Orthop Res.* 2023;41: 7-20. doi:10.1002/jor.25463